Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
AGMB Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: February 27, 2026
Report Source: 2025 3rd Quarter Report
Agomab Therapeutics NV. Stock Analysis AGMB
United States Health Care Small Cap Report: AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The firm is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The firm also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
Read More Agomab Therapeutics NV (AGMB) Chart
Key Statistics of Agomab Therapeutics NV (AGMB)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$12.10Volume
54.27KP/E Ratio (TTM)
-52 Week Range
Market Cap
521.48MAvg. Volume
104.52KDividend Yield
-Financial Metrics & Statements of Agomab Therapeutics NV (AGMB)
FAQ's for Agomab Therapeutics NV (AGMB)
- According to Musaffa’s Shariah screening methodology, Agomab Therapeutics NV (AGMB) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Agomab Therapeutics NV using these criteria to determine its compliance status.
- Muslim investors may consider investing in Agomab Therapeutics NV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Agomab Therapeutics NV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Agomab Therapeutics NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Agomab Therapeutics NV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.